Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone

World Journal of Gastroenterology

Volumn 12, Issue 43, 2006, Pages 6973-6981

  Xie, De Rong ^a   Liang, Han Lin ^a   Wang, Yu ^b   Guo, Shuan Shuan ^a   Yang, Qiong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Central Hospital of Jiangmen   (China)

Author keywords

Chemotherapy; Gemcitabine; Meta analysis; Pancreatic cancer

Indexed keywords

4 N ACETYLDINALINE; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MARIMASTAT; NSC 631570; OXALIPLATIN; PEMETREXED; PLACEBO; TIPIFARNIB; UKRAIN;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DIARRHEA; DISEASE SEVERITY; EMBASE; HUMAN; INFECTION; INOPERABLE CANCER; MEDLINE; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCREAS CANCER; QUANTITATIVE ANALYSIS; REGISTER; REMISSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

EID: 33751552368     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i43.6973     Document Type: Article

References (32)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
2. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
3. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000; 320: 1574-1577
4. Degen G, Hong Z. Treatment effectiveness evaluation of gemcitabine for pancreatic cancer. Zhonghua Fubu Jibing Zazhi 2003; 3: 570-571
5. Ohkawa S. Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2004; 22: 4131
6. Richards DA, Oettle H, Vervenne WL, Saif MW, Thomas JP, Spitzer G, Visseren-Grul C, Enas N and Weitzman A. Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs GEM plus placebo in advanced adenocarcinoma of the pancreas. J Clin Oncol 2005; 23: 4092
7. Shapiro J, Marshall J, Karasek P, Figer A, Oettle H, Couture F, Jeziorski K, Broome P and Hawkins R. G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol 2005; 23: 4012
8. Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003; 14: 97-104
9. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94: 902-910
10. Wang XY, Ni QX, Jin ML, Li ZS, Wu YX, Zhao YP and Feng FY. Gemcitabine or gemcitabine plus cisplatin for in patients with locally advanced or metastatic pancreatic cancer. Zhonghua Fubu Jibing Zazhi 2002; 24: 404-407
11. Gansauge F, Ramadani M, Pressmar J, Gansauge S, Muehling B, Stecker K, Cammerer G, Leder G, Beger HG. NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Langenbecks Arch Surg 2002; 386: 570-574
12. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275
13. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-167
14. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438
15. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516
16. O'Reilly EM, Abou-Alfa GK, Letourneau R, Harker WG, Modiano M, Hurwitz H, Tchekmedyian NS, Ackerman J, De Jager RL and Eckhardt SG. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 2004; 22: 4006
17. Richards DA, Oettle H, Ramanathan R, Ramanathan RK, Van Laethem J-L, Peeters M, Fuchs M, John W, Arning M and Von Hoff D. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol 2004; 22: 4007
18. Li CP, Chao Y. A prospective randomized trial of gemcitabine alone or gemcitabine + cisplatin in the treatment of metastatic pancreatic cancer. J Clin Oncol 2004; 22: 4144
19. Reni M, Cordio S, Passardi A, Panucci MG, Passoni P, Oliani C, Luppi G, Galli L, Nicoletti R and Villa E. Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA). J Clin Oncol 2004; 22: 4010
20. Viret F, Ychou M, Lepille D, Mineur L, Navarro F, Topart D, Fonck M, Goineau J, Madroszyk-Flandin A and Chouaki N. Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study. J Clin Oncol 2004; 22: 4118
21. Rocha Lima CMS, Rotche R, Jeffery M, Trudeau M, Cisar L A, Morganti A, Gruia G, Miller L and Green MR. A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Oncol 2003; 22: 1005
22. Di Costanzo F, Sdrobolini A, Carlini P, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P and Ospedaliera S A. Gemcitabine (GEM) Alone or in Combination with 5-FU Continuous Infusion (CI) in the Treatment of Advanced Pancreatic Cancer (APC): a GOIRC Randomized Phase II Trial. Proc Am Soc Clin Oncol 2001; 20: 612
23. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Stoffregen C and Clemens M. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 2003; 22: 1003
24. Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR and Mayer RJ. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). J Clin Oncol 2004; 22: 4011
25. Richards DA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Dasse KD, Macdonald K, Gulyas S, Plante M, Copley-Merriman C and Grove W. Randomized, double-blind, placebo-controlled phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine (CI-994+G) versus placebo plus gemcitabine (P+G) in the treatment of patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 2002; 21: 644
26. Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, Nomikos D, Ding K, Ptaszynski M and Parulekar W. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. 2005 Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to Gastrointestinal Malignancies and Premalignancies; 2005 January 27-29; Hollywood, FL: Abstract 77
27. Stathopoulos G, Aravantinos G, Syrigos K, Kalbakis K, Karvounis N, Papakotoulas P, Boukovinas J, Potamianou A, Polyzos A, Christophillakis C and Georgoulias V. A randomized phase III study of irinotecan/ gemcitabine combination versus gemcitabine in patients with advanced/ metastatic pancreatic cancer. J Clin Oncol 2005; 23: 4106
28. Riess H, Helm A, Niedergethmann M, Schmidt-Wolf I, Moik M, Hammer C, Zippel K, Weigang-Köhler K, Stauch M and Oettle H. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 4009
29. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, Schueller J, Bernhard J, Dietrich D and Scheithauer W. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 2005; 23: 4010
30. Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 1997; 24: S7-8-S7-16
31. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996; 2: 521-530
32. Xie DR, Liang HL, Wang Y, Guo SS. Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone. Chin J Dig Dis 2006; 7: 49-54